SYRS News and Press, Syros Pharmaceuticals Inc.

2024-07-02 12:56:55 ET Summary Syros Pharmaceuticals focuses on developing therapies for myeloid cancers. The main pipeline candidate is tamibarotene, with positive signals in phase 2 trial and a key data readout coming in Q4 2024. Financially, SYRS has $112.2 million in asset...

2024-06-18 10:10:00 ET June 18, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform covering biotech and medical technology stocks releases the second of a two-part series looking at developments for the treatment of blood cancers, including AML, featuring A...

-- Three medical experts will join members of Syros’ leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatment landscape, and the opportunity for tamibarotene on Tuesday, June 25 at 11:00 a.m. ET -- -- Syros expects to rep...

2024-05-27 04:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-17 13:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-14 10:52:51 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Syros Pharmaceuticals (NASDAQ: SYRS ) just reported results for the first quarter of 2024. Syros Pharmaceuticals reported earnings per share of -10 cents. This was above t...

2024-05-14 10:19:02 ET Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Conference Call May 14, 2024, 08:30 AM ET Company Participants Karen Hunady - Director of IR and Corporate Communications Conley Chee - CEO David Roth - CMO Jason Haas - CFO Conf...

2024-05-14 07:31:19 ET More on Syros Pharmaceuticals Syros jumps on FDA fast track tag for leukemia drug Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals Read the full article on Seeking Alpha ...

– Passed Interim Futility Analysis of the Primary Endpoint in Phase 3 SELECT-MDS-1 Trial of Tamibarotene; Pivotal CR Data Expected by Mid-4Q 2024; Company to Host HR-MDS-focused Webcast Event with Medical Experts on June 25, 2024 – – Received FDA Fast Track Designatio...

2024-05-13 12:10:49 ET More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcript Syros jumps on FDA fast track tag for leukemia drug Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $1.6M ...